Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

PURPOSE: Ruxolitinib is an oral Janus kinase (JAK) 1/JAK2 inhibitor approved in the US for the treatment of intermediate-or high-risk myelofibrosis (MF). Because thrombopoietin and erythropoietin signal through JAK2, dose-dependent cytopenias are expected with treatment. In the COMFORT-I (COntrolled...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Main Authors:	Verstovsek, Srdan, Gotlib, Jason, Gupta, Vikas, Atallah, Ehab, Mascarenhas, John, Quintas-Cardama, Alfonso, Sun, William, Sarlis, Nicholas J, Sandor, Victor, Levy, Richard S, Kantarjian, Hagop M, Mesa, Ruben A
Format:	Artigo
Sprog:	Inglês
Udgivet:	Dove Medical Press 2013
Fag:	Original Research
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3869911/ https://ncbi.nlm.nih.gov/pubmed/24368888 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S53348
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

Lignende værker